GVR Report cover Personalized Medicine Biomarkers Market Size, Share & Trends Report

Personalized Medicine Biomarkers Market Size, Share & Trends Analysis Report By Technology (Liquid Biopsy), By Application (Oncology, Cardiology), By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453386
  • Number of Pages: 0
  • Format: Electronic (PDF)

The growth of the personalized medicine biomarkers market is attributed to increasing demand and growing awareness about personalized medicine among healthcare professionals. In addition, rising approval for companion diagnostic tests for cancer drugs is expected to boost growth. For instance, in July 2021, Labcorp launched therascreen KRAS PCR Mutation Analysis for all solid malignancies, a companion test for Amgen’s lung cancer therapy.

Biomarkers are essential tools for determining the optimal course of action for people with a specific disease. Every patient is expected to receive safe and efficient therapies as a result of the creation of personalized medications using biomarkers. One example of an individualized treatment that makes use of biomarkers is the drug irinotecan (Camptosar), which is used in chemotherapy. Irinotecan is a medication that is used to treat colorectal cancer. Irinotecan's toxicity has long been a source of concern, but with the use of biomarkers, it is now safer and better able to identify patients at high risk of developing side effects. Moreover, increasing use of personalized medicine in the treatment of skin cancer to provide more effective diagnosis and treatment with the aid of biomarkers is further increasing its adoption.

North America dominated the overall market in 2021 which can be attributed to increasing funding for biomarkers aided by technological advancements, high disposable income, and the presence of key market players operating in the region. The U.S. has the largest share of personalized medicines in the region owing to increasing private and public initiatives and raising awareness among the population about chronic diseases and treatments. Moreover, key players are focusing on developing novel products to maintain their dominance over the market. For instance, in February 2022, FoundationOne CDx received U.S. FDA approval as a companion diagnostic for Keytruda to identify patients with microsatellite instability-high solid tumors. 

Personalized Medicines Biomarkers Market Segmentation

Segments

Details

By Technology

  • Liquid Biopsy
  • Others

By Application

  • Oncology
  • Cardiology
  • Neurology
  • Immunology
  • Others

 

Major companies operating in the market includeNovartis AG, Pfizer Inc., Catalent, Inc., Johnson & Johnson Services, Inc, AstraZeneca, Bristol-Myers Squibb Company, Amgen Inc., Gilead Sciences, Inc., Merck KGaA, Eli Lilly and Company, AbbVie Inc., Parexel International Corporation., F. Hoffmann-La Roche Ltd., and Bayer AG. These players are focusing on mergers and acquisitions to maintain their presence in the market. For instance, in June 2022, GRAIL and AstraZeneca formed a strategic partnership to create companion diagnostic tests that would enable the treatment of early-stage cancer.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.